The role of complement in IgA nephropathy

Area of Science:

• Nephrology
• Immunology
• Complement System Biology

Background:

• IgA nephropathy (IgAN) is a prevalent kidney disease with variable clinical and histological presentations.
• The precise mechanisms driving IgAN pathogenesis, particularly glomerular inflammation and injury, remain incompletely understood.
• Established associations exist between IgAN and markers of complement activation, but the specific pathways and their contributions are not fully defined.

Purpose of the Study:

• To elucidate the role of specific complement pathways and proteins in IgA nephropathy pathogenesis.
• To investigate the contribution of complement deregulation to glomerular inflammation and renal injury in IgAN.
• To identify potential biomarkers for predicting IgAN progression and therapeutic targets for complement inhibition.

Main Methods:

• Review of recent scientific literature identifying specific complement pathways and proteins in severe IgAN cases.
• Analysis of established associations between IgAN and glomerular and circulating markers of complement activation.
• Exploration of the pathogenic roles of complement factor H related proteins 1 and 5, and the lectin pathway in IgAN.

Main Results:

• Recent findings implicate specific complement pathways, including factor H related proteins 1 and 5 and the lectin pathway, in the pathogenesis of severe IgAN.
• Evidence suggests that complement deregulation and activation are significant drivers of renal injury in a subset of IgAN patients.
• Markers of complement activation may serve to identify IgAN patients at higher risk for progressive renal impairment.

Conclusions:

• Complement system dysregulation plays a critical role in IgA nephropathy, particularly in severe forms of the disease.
• Targeting specific complement pathways, such as those involving factor H related proteins and the lectin pathway, may offer novel therapeutic strategies for IgAN.
• Complement inhibition holds promise for preventing and reducing glomerular injury, potentially altering the course of IgAN and preventing end-stage renal disease.